Hannah Clarke

“The results of the current study indicate that 100% of the elderly patients who were referred for PSMA PET/CT on the basis of clinical suspicion only were found to have avid disease," said Einat Even-Sapir, MD, PhD.

"The next-generation Optilume BPH Catheter System offers a safe and effective new, minimally invasive treatment for BPH, reducing urinary obstruction with a low rate of sexual or other adverse effects," says Steven A. Kaplan, MD.

A total of 158 patients with NMIBC including tumors with stage carcinoma in situ, Ta, and T1 were enrolled in the prospective trial in mainland China.

The urine-based assay measures the expression of HOXC6 and DLX1 to determine whether a patient may benefit from prostate biopsy.

The novel test was developed and validated using the biomarkers Appl1, Sortilin, and Syndecan-1 that were studied by investigators at the University of South Australia.

The studies explored the use of opioids following surgery as well as the risk of incisional hernia.

"In patients with prostate cancer considered for surgery, PSMA-PET can provide information on the risk of recurrence after surgery, before the surgery even happens," says Loïc Djaïleb, MD, PhD.

"The study revealed that the anatomical changes in the male pelvis could potentially favor the upright position for prostate treatments,” says Niek Schreuder.

"[Our study] suggests that limiting added sugar intake may help to prevent the formation of kidney stones,” says Shan Yin, MD.

Patients classified as high-risk by the genomic classifier who underwent radical prostatectomy had a 3-fold higher risk of harboring adverse pathology at the time of surgery compared with those with low-risk.

Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.

"Patients and providers should be aware of the long-term risks of radiation exposure when weighing treatment decisions,” says Avi Baskin, MD, MPhil.

Urologist Rachel S. Rubin, MD, highlights her specialized sexual medicine practice that provides care to patients of all genders.

Due to rigorous data collection, there has been very little dropout and 3-year OS and PFS compare favorably to alternate regimens such as ipilimumab nivolumab,” says Elizabeth R. Plimack, MD, MS,

"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.

“Our study shows that these patients can immediately benefit from supervised exercise interventions to improve their sexual health and that exercise should be considered as an integral part of treatment for prostate cancer,” says Daniel Galvao, PhD.

"In the setting of BCG shortages, our patients need alternatives that do not deprive them of the chance of cure," says Ashish M. Kamat, MD, MBBS.

“Increasing the representation of physicians (or actors) who appear concordant with the target audience may be an important tool for more effective health communication strategies to mitigate health disparities," the authors write.

The approval comes after a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use in May 2023.

In this installment, sisters Amy Pearlman, MD, and Michelle Pearlman, MD, highlight Prime Institute, the practice they co-founded in South Florida.

"Despite prevalent OAB symptoms, only 6% of all LUTS prescriptions in men were for OAB medications," says Sarah Neu, MD, MSd, FRCSC.

The phase 3 ATLAS and ENVISION trials are exploring UGN-102 for intravesical solution in patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

"The thing that's unique about this course, in my opinion, is that we are combining the vaginoplasty and phalloplasty discussions," says Kirtishri Mishra, MD.

In total, 73% of patients showed an increase in 24-hour urine volume from baseline to the end of the 1-month trial period.

In total, 77.8% of Black respondents, 72.7% of Asian respondents, 57.1% of Latino respondents, and 46.5% of White respondents indicated that the racial and ethnic diversity of residents at a program influenced their decision to preference signal or sub-internship with that program.

The UroActive device is currently being studied in the SOPHIA study, which published initial results earlier this year.

Dr. Vince has an interest in disparities in urologic care, specifically among patients with prostate cancer.

"Extra support from trusted peers can help make navigating complex health care systems easier for transgender patients, who often have to wait years before receiving gender-affirming genital surgery—while also managing the stress and trauma associated with being part of a society that often doesn’t accept non-conforming gender expression,” says Geolani Dy, MD, FACS

ARX517 is currently being studied in the phase 1/2 open-label APEX-01 trial.

Data among patients with follow-up of greater than 48 months demonstrated an IPSS reduction of 45.2% from baseline to 79 months following treatment.